Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 11;7(1):11121.
doi: 10.1038/s41598-017-08848-4.

A de novo substructure generation algorithm for identifying the privileged chemical fragments of liver X receptorβ agonists

Affiliations

A de novo substructure generation algorithm for identifying the privileged chemical fragments of liver X receptorβ agonists

He Peng et al. Sci Rep. .

Abstract

Liver X receptorβ (LXRβ) is a promising therapeutic target for lipid disorders, atherosclerosis, chronic inflammation, autoimmunity, cancer and neurodegenerative diseases. Druggable LXRβ agonists have been explored over the past decades. However, the pocket of LXRβ ligand-binding domain (LBD) is too large to predict LXRβ agonists with novel scaffolds based on either receptor or agonist structures. In this paper, we report a de novo algorithm which drives privileged LXRβ agonist fragments by starting with individual chemical bonds (de novo) from every molecule in a LXRβ agonist library, growing the bonds into substructures based on the agonist structures with isomorphic and homomorphic restrictions, and electing the privileged fragments from the substructures with a popularity threshold and background chemical and biological knowledge. Using these privileged fragments as queries, we were able to figure out the rules to reconstruct LXRβ agonist molecules from the fragments. The privileged fragments were validated by building regularized logistic regression (RLR) and supporting vector machine (SVM) models as descriptors to predict a LXRβ agonist activities.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
The flow-chart for using de novo substructure generation algorithm to discover LXRβ agonist privileged fragments and elucidate the assembly rules.
Figure 2
Figure 2
LXRβ, PPARα and VR libraries were discriminated by the frequent substructure descriptors derived from the ZINC library.
Figure 3
Figure 3
The performances of three substructure-based SVM regression models. (A) LXRβ, (B) PPARα, (C) VR.
Figure 4
Figure 4
The schema of Rule 1.
Figure 5
Figure 5
The schema of Rule 2.
Figure 6
Figure 6
LXRβ ligands created by merging Fragments B, C and F (Rule 3).
Figure 7
Figure 7
Bioisostere definitions for Fragments A’ and D’.
Figure 8
Figure 8
LXRβ ligands generated by Rule 4.
Figure 9
Figure 9
LXRβ agonists constructed by Rule 5.
Figure 10
Figure 10
Scaffold constructed by rule 6.
Figure 11
Figure 11
Scaffold constructed by Rule 7. The structure on the right is GW3965.
Figure 12
Figure 12
Scaffold constructed by Rule 8.
Figure 13
Figure 13
PCA plot for the compounds in the LXRβ library using the frequent fragment descriptors derived from ZINC database. Privileged fragments and their combinations are coded in different colors. The compounds with the same color are aggregated.
Figure 14
Figure 14
The experimentally confirmed LXRβ agonistic compounds found based upon the rules of privileged fragments and their combinations. At compound 3, R is a halogenated long-hydrocarbon substituent.
Figure 15
Figure 15
The activities of the confirmed LXRβ agonistic compounds and their fragment combination patterns. The letters above the bars represent the privileged fragments discovered by our algorithm. The structure of GW3965 is depicted in Fig. 11.
Figure 16
Figure 16
An example of a substructure generation tree. The tree started with a four compounds library with a C-C root fragment with a subID vector containing {An Bm Ch De Dk}. The popularity of this root fragment is 4. The root node produced two successor nodes (Node-11 and Node-12) by generating two new substructures. The process is repeated till all successor nodes are undividable. The substructures in the thick boxes are all possible fragment substructures created from a C-C root fragment. Other types of root fragments will be used to generate more substructure generation trees.
Figure 17
Figure 17
Pruning a substructure generation tree. The tree was growing while a depth-first search was proceeding. The nodes in black boxes were calculated on the fly. The nodes in green boxes were kept in an substructure library. The nodes in red boxes were pruned.
Figure 18
Figure 18
FFID and frequent substructures. Case 1: One FFID could have more than one fragments, one of the fragments was the substructure of another. The larger fragment was kept in this case. Case 2: One FFID could have more than one fragments, they were not topologically included to each other. Both fragments would be assigned to the same FFID.

Similar articles

Cited by

References

    1. Hong C, Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nature reviews. Drug discovery. 2014;13:433–444. doi: 10.1038/nrd4280. - DOI - PubMed
    1. Lin C-Y, Vedin L-L, Steffensen KR. The emerging roles of liver X receptors and their ligands in cancer. Expert Opinion on Therapeutic Targets. 2016;20:61–71. doi: 10.1517/14728222.2015.1081169. - DOI - PubMed
    1. Zhao W, et al. Three-dimensional pharmacophore modeling of liver-X receptor agonists. Journal of chemical information and modeling. 2011;51:2147–2155. doi: 10.1021/ci100511v. - DOI - PubMed
    1. Li Y, et al. Predicting selective liver X receptor b agonists using multiple machine learning methods. Molecular BioSystems. 2015;11:1241–1250. doi: 10.1039/C4MB00718B. - DOI - PubMed
    1. Temml V, Voss CV, Dirsch VM, Schuster D. Discovery of New Liver X Receptor Agonists by Pharmacophore Modeling and Shape-Based Virtual Screening. Journal of chemical information and modeling. 2014;54:367–371. doi: 10.1021/ci400682b. - DOI - PMC - PubMed

Publication types

LinkOut - more resources